AbelZeta Overview

  • Year Founded
  • 2001

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 217

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $120M

  • Investors
  • 8

AbelZeta General Information

Description

Developer of T cell-based therapeutics designed to address unmet medical needs in oncology and immunological diseases. The company focuses on the discovery, development, and manufacturing of personalized cell therapies targeting hematologic malignancies, solid tumors, and inflammatory and immunological conditions, enabling oncologists and immunologists to access novel treatment modalities for patients with cancer and autoimmune disorders who have limited alternatives under existing standard-of-care protocols.

Contact Information

Formerly Known As
ATC Technology, Cellular Biomedicine Group, CBMG Holdings
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Venture Capital-Backed
Corporate Office
  • 9605 Medical Center Drive
  • Suite 100
  • Rockville, MD 20850
  • United States
+1 (240)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Vertical(s)
Corporate Office
  • 9605 Medical Center Drive
  • Suite 100
  • Rockville, MD 20850
  • United States
+1 (240)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AbelZeta Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Later Stage VC (Series A) 29-Sep-2021 $120M Completed Clinical Trials - Phase 1
10. Merger/Acquisition 19-Feb-2021 Completed Clinical Trials - Phase 1
9. Secondary Transaction - Open Market Completed Clinical Trials - Phase 1
8. PIPE 30-Jan-2018 Completed Clinical Trials - Phase 1
7. PIPE 28-Dec-2017 Completed Clinical Trials - Phase 1
6. PIPE 19-Apr-2016 Completed Clinical Trials - Phase 1
5. PIPE 07-Apr-2015 Completed Clinical Trials - Phase 1
4. PIPE 16-Jul-2014 Completed Clinical Trials - Phase 1
3. PIPE 11-Apr-2014 $6.91M $9.9M Completed Clinical Trials - Phase 1
2. PIPE 26-Jul-2013 $3M $3M Completed Clinical Trials - Phase 1
To view AbelZeta’s complete valuation and funding history, request access »

AbelZeta Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of T cell-based therapeutics designed to address unmet medical needs in oncology and immunological diseases. T
Drug Discovery
Rockville, MD
217 As of 2019

San Carlos, CA
 

Fort Lauderdale, FL
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

AbelZeta Competitors (34)

One of AbelZeta’s 34 competitors is Iovance Biotherapeutics, a Corporation company based in San Carlos, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Iovance Biotherapeutics Corporation San Carlos, CA
Alaunos Therapeutics Formerly VC-backed Fort Lauderdale, FL
Sorrento Therapeutics Formerly VC-backed San Diego, CA
Ayala Pharmaceuticals Corporation Wilmington, DE
PersonGen BioTherapeutics Venture Capital-Backed Suzhou, China
You’re viewing 5 of 34 competitors. Get the full list »

AbelZeta Patents

AbelZeta Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026222428-A1 Cll-1/cd33 dual-targeting chimeric antigen receptors Pending 18-Apr-2025
WO-2026151675-A1 Bispecific chimeric antigen receptors targeting cd20 and bcma Pending 07-Jan-2025
AU-2024255572-A1 Bispecific chimeric antigen receptors targeting bcma and cd19 Pending 11-Apr-2023
EP-4695301-A2 Bispecific chimeric antigen receptors targeting bcma and cd19 Pending 11-Apr-2023
US-20260027156-A1 Bispecific chimeric antigen receptors targeting bcma and cd19 Pending 11-Apr-2023 A61K35/17
To view AbelZeta’s complete patent history, request access »

AbelZeta Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AbelZeta Former Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Alumni Ventures Venture Capital Minority
EastBridge Investment Group Corporation Minority
Sailing Capital PE/Buyout Minority
To view AbelZeta’s complete investors history, request access »

AbelZeta Investments & Acquisitions (6)

AbelZeta’s most recent deal was a Corporate Asset Purchase with University of South Florida (GVAX vaccine) for . The deal was made on 29-Jun-2015.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
University of South Florida (GVAX vaccine) 29-Jun-2015 Corporate Asset Purchase Buildings and Property
Chinese PLA General Hospital (CAR-T cell technology) 09-Feb-2015 Corporate Asset Purchase Buildings and Property
Agreen Biotech 30-Sep-2014 Merger/Acquisition Other Healthcare Services
BioMed Immunotech 02-Aug-2014 Merger/Acquisition Other Commercial Products
EastBridge Investment Group 06-Feb-2013 Merger/Acquisition Investment Banks
You’re viewing 5 of 6 investments and acquisitions. Get the full list »

AbelZeta Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
BioMed Immunotech

AbelZeta FAQs

  • When was AbelZeta founded?

    AbelZeta was founded in 2001.

  • Where is AbelZeta headquartered?

    AbelZeta is headquartered in Rockville, MD.

  • What is the size of AbelZeta?

    AbelZeta has 217 total employees.

  • What industry is AbelZeta in?

    AbelZeta’s primary industry is Drug Discovery.

  • Is AbelZeta a private or public company?

    AbelZeta is a Private company.

  • What is AbelZeta’s current revenue?

    The current revenue for AbelZeta is .

  • How much funding has AbelZeta raised over time?

    AbelZeta has raised $120M.

  • Who are AbelZeta’s investors?

    Alumni Ventures, EastBridge Investment Group, and Sailing Capital have invested in AbelZeta.

  • Who are AbelZeta’s competitors?

    Iovance Biotherapeutics, Alaunos Therapeutics, Sorrento Therapeutics, Ayala Pharmaceuticals, and PersonGen BioTherapeutics are some of the 34 competitors of AbelZeta.

  • When was AbelZeta acquired?

    AbelZeta was acquired on 29-Sep-2021.

  • Who acquired AbelZeta?

    AbelZeta was acquired by GIC Private.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process